Area:
Neuroscience Biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Hibiki K. Fujita is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 2006 — 2007 |
Fujita, Hibiki |
F31Activity Code Description:
To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
The Pathogenic Mechanisms of Mutant Ant1 Myopathy @ Weill Medical College of Cornell Univ
[unreadable] DESCRIPTION (provided by applicant): In this proposal, I will investigate the molecular and biochemical mechanisms of autosomal dominant progressive external opthalmoplegia (adPEO) with mitochondrial DMA multiple deletions, which is caused by mutations in the adenine nucleotide translocator (ANT) 1. Because ANT transports ADP and ATP across the mitochondrial inner membrane, it is a key player in ATP production and energy metabolism. ANT is also implicated in apoptosis initiated in mitochondria. Although the genetic causes of ANT1 adPEO are known, its pathogenic mechanisms remain undetermined. Mitochondrial abnormalities resulting from mutant ANT1 have been reported in yeast models. However, such abnormalities have not yet been studied in mammalian systems because ANT1 expression leads to apoptosis in most cultured mammalian cell types. In this study, pathogenic ANT1 mutations will be expressed in disease-pertinent skeletal and heart myocytes. Preliminary studies show that expression of ANT1 using adenoviral vectors in myocyte cultures is feasible without causing overt cell death. To investigate the pathogenesis of ANT1 adPEO I will determine the effects of ANT1 mutations on ANT function and structure, mitochondrial bioenergetics, mitochondrial DNA stability, and apoptosis, in muscle cells. [unreadable] [unreadable]
|
0.915 |